Please assess the completion status of the following clinical trial:

Trial Title: To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with cirrhosis of liver with signs of parkinsonisms~* Patients consented for the study protocol by signing the informed consent.~Exclusion Criteria:~* Age \< 18 years.~* Patient s with HCC (Hepatocellular Carcinoma).~* Patients diagnosed as Wilsons disease.~* Patient who withdrew or non complaint to the study protocol.~* ALF (Acute Liver failure)~* Classical Parkinsonism~* Atypical Parkinsonism~* Pregnancy~* Hypotension~* Uncontrolled hypertension~* CAD~* Psychiatric illness~* Acute episode of Hepatic encephlopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lactulose + Rifaximin + Bromocriptine (Type: EXPERIMENTAL): None
- Lactulose+Rifaximin+Placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).